These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11943391)

  • 1. Differences in the intracellular fate of free and polymer-bound doxorubicin.
    Hovorka O; St'astný M; Etrych T; Subr V; Strohalm J; Ulbrich K; Ríhová B
    J Control Release; 2002 Apr; 80(1-3):101-17. PubMed ID: 11943391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs.
    Ríhová B; Strohalm J; Kubácková K; Jelínková M; Hovorka O; Kovár M; Plocová D; Sírová M; St'astný M; Rozprimová L; Ulbrich K
    J Control Release; 2002 Jan; 78(1-3):97-114. PubMed ID: 11772452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPMA based macromolecular therapeutics: internalization, intracellular pathway and cell death depend on the character of covalent bond between the drug and the peptidic spacer and also on spacer composition.
    Hovorka O; Etrych T; Subr V; Strohalm J; Ulbrich K; Ríhová B
    J Drug Target; 2006 Jul; 14(6):391-403. PubMed ID: 17092839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
    Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
    Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
    Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
    Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy.
    Beyer U; Rothern-Rutishauser B; Unger C; Wunderli-Allenspach H; Kratz F
    Pharm Res; 2001 Jan; 18(1):29-38. PubMed ID: 11336350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line.
    Kunath K; Kopecková P; Minko T; Kopecek J
    Eur J Pharm Biopharm; 2000 Jan; 49(1):11-5. PubMed ID: 10613922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage.
    Nakamura H; Etrych T; Chytil P; Ohkubo M; Fang J; Ulbrich K; Maeda H
    J Control Release; 2014 Jan; 174():81-7. PubMed ID: 24269967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
    Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
    J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
    Omelyanenko V; Kopecková P; Gentry C; Kopecek J
    J Control Release; 1998 Apr; 53(1-3):25-37. PubMed ID: 9741911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators.
    Ríhová B; Jelínková M; Strohalm J; Subr V; Plocová D; Hovorka O; Novák M; Plundrová D; Germano Y; Ulbrich K
    J Control Release; 2000 Feb; 64(1-3):241-61. PubMed ID: 10640661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.
    Ríhová B; Jelínková M; Strohalm J; St'astný M; Hovorka O; Plocová D; Kovár M; Dráberová L; Ulbrich K
    Bioconjug Chem; 2000; 11(5):664-73. PubMed ID: 10995209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro.
    Omelyanenko V; Gentry C; Kopecková P; Kopecek J
    Int J Cancer; 1998 Feb; 75(4):600-8. PubMed ID: 9466663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction-responsive disassemblable core-cross-linked micelles based on poly(ethylene glycol)-b-poly(N-2-hydroxypropyl methacrylamide)-lipoic acid conjugates for triggered intracellular anticancer drug release.
    Wei R; Cheng L; Zheng M; Cheng R; Meng F; Deng C; Zhong Z
    Biomacromolecules; 2012 Aug; 13(8):2429-38. PubMed ID: 22746534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric anticancer drugs with pH-controlled activation.
    Ulbrich K; Etrych T; Chytil P; Pechar M; Jelinkova M; Rihova B
    Int J Pharm; 2004 Jun; 277(1-2):63-72. PubMed ID: 15158969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics I. Differential centrifugation fractionation B16F10 cells and use to study the intracellular fate of HPMA copolymer - doxorubicin.
    Seib FP; Jones AT; Duncan R
    J Drug Target; 2006 Jul; 14(6):375-90. PubMed ID: 17092838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance.
    Braunová A; Kostka L; Sivák L; Cuchalová L; Hvězdová Z; Laga R; Filippov S; Černoch P; Pechar M; Janoušková O; Šírová M; Etrych T
    J Control Release; 2017 Jan; 245():41-51. PubMed ID: 27871991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond.
    Ríhová B; Etrych T; Sírová M; Kovár L; Hovorka O; Kovár M; Benda A; Ulbrich K
    Mol Pharm; 2010 Aug; 7(4):1027-40. PubMed ID: 20524698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio.
    Baabur-Cohen H; Vossen LI; Krüger HR; Eldar-Boock A; Yeini E; Landa-Rouben N; Tiram G; Wedepohl S; Markovsky E; Leor J; Calderón M; Satchi-Fainaro R
    J Control Release; 2017 Jul; 257():118-131. PubMed ID: 27374630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.